Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) Research & Development (2016 - 2025)

Historic Research & Development for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $2.3 million.

  • Orthopediatrics' Research & Development fell 946.84% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1160.33%. This contributed to the annual value of $11.0 million for FY2024, which is 127.58% up from last year.
  • Per Orthopediatrics' latest filing, its Research & Development stood at $2.3 million for Q3 2025, which was down 946.84% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Orthopediatrics' Research & Development registered a high of $3.0 million during Q1 2024, and its lowest value of $1.3 million during Q3 2021.
  • Over the past 5 years, Orthopediatrics' median Research & Development value was $2.4 million (recorded in 2025), while the average stood at $2.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 6977.68% in 2023, then tumbled by 2158.11% in 2025.
  • Quarter analysis of 5 years shows Orthopediatrics' Research & Development stood at $1.6 million in 2021, then soared by 53.73% to $2.5 million in 2022, then increased by 18.2% to $2.9 million in 2023, then fell by 0.21% to $2.9 million in 2024, then fell by 19.99% to $2.3 million in 2025.
  • Its Research & Development was $2.3 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.4 million in Q1 2025.